Stoke Therapeutics, Inc.
STOK
$26.10
-$3.94-13.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 52.49M | 50.27M | -88.98M | -105.46M | -103.57M |
| Total Depreciation and Amortization | 1.99M | 2.09M | 2.18M | 2.28M | 2.37M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.05M | 29.02M | 28.09M | 27.71M | 27.19M |
| Change in Net Operating Assets | -22.93M | -11.84M | -28.14M | -8.84M | -5.95M |
| Cash from Operations | 61.60M | 69.54M | -86.85M | -84.31M | -79.95M |
| Capital Expenditure | -451.00K | -343.00K | -203.00K | -390.00K | -670.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -163.58M | -103.49M | -107.27M | -93.13M | -48.23M |
| Cash from Investing | -164.03M | -103.83M | -107.48M | -93.52M | -48.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.66M | 130.75M | 131.09M | 137.87M | 130.27M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10.66M | 130.75M | 131.09M | 137.87M | 130.27M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.78M | 96.46M | -63.23M | -39.96M | 1.42M |